Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 21 Results

Intervention Indication Therapeutic Area Year Actions
Anakinra for Still’s disease Anakinra (Kineret) Juvenile idiopathic arthritis Rheumatology 2018 View  |  Download
Baricitinib for treating juvenile idiopathic arthritis in paediatric patients Baricitinib (LY3009104; Olumiant) Juvenile psoriatic arthritis Rheumatology 2022 View  |  Download
Bimekizumab for active psoriatic arthritis Bimekizumab (UCB4940) Psoriatic arthritis Dermatology , Rheumatology 2021 View  |  Download
Bimekizumab for non-radiographic axial spondyloarthritis Bimekizumab (UCB4940) Axial spondyloarthritis Rheumatology 2021 View  |  Download
Deucravacitinib for treating active psoriatic arthritis Deucravacitinib (BMS-986165) Psoriatic arthritis Dermatology , Rheumatology 2023 View  |  Download
Filgotinib for moderate to severe active rheumatoid arthritis Filgotinib (GLPG-0634; filgotinib maleate) , Methotrexate (MTX; Otrexup; Vibex MTX; MQX-5902; methotrexate disodium; methotrexate sodium) , other nonbiologic DMARDs Rheumatoid arthritis Rheumatology 2019 View  |  Download
Guselkumab for active psoriatic arthritis Guselkumab (Tremfya; CNTO-1959) Psoriatic arthritis Dermatology , Rheumatology 2019 View  |  Download
Ixekizumab for axial spondyloarthritis Ixekizumab (Taltz; LY2439821) Spondyloarthritis Musculoskeletal System , Rheumatology 2018 View  |  Download
Otilimab in combination with conventional synthetic DMARDs for treating rheumatoid arthritis Otilimab Rheumatoid arthritis Rheumatology 2022 View  |  Download
Risankizumab (by subcutaneous injection) for Active Psoriatic Arthritis After Inadequate Control or Intolerance to Conventional Drugs Risankizumab (BI 655066; Skyrizi; ABBV 066) Psoriatic arthritis Dermatology , Rheumatology 2017 View  |  Download
1 2 3
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications